DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss the Company’s third quarter 2023 financial

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate via fireside chat at the 2023 Cantor Global Healthcare Conference.

– Dutch Ministry of Health Approves VAZKEPA ® (icosapent ethyl) for National Reimbursement to Reduce the Risk of Cardiovascular Events in Patients with Established Cardiovascular Disease – – Italy’s AIFA Pricing & Reimbursement Committee (CPR) Issues Negative Decision on VAZKEPA; Follows Positive

-- Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA ® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –- -- Heart Disease Second Leading Cause

-- VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHSScotland, as secondary prevention in adult statin-treated patients at high  cardiovascular risk 1   -- -- VAZKEPA® already commercially available in England, Wales, and Northern Ireland

-- Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License and Royalty Revenues, of Which $11 Million is Non-Cash -- -- Delivered Positive Cash Flow of $9 Million in the Quarter with a Cash

Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region DUBLIN, Ireland and BRIDGEWATER, N.J. and NANTOU, Taiwan, July 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and Lotus

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023.

-- Spain’s Drug Pricing Committee recommends reimbursement of VAZKEPA ® (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in patients with high cardiovascular risk 1 -- -- Positive recommendation marks the final step in the reimbursement process in Spain following months of active

– Agreement Underscores Board’s Commitment to Aligning Executive Compensation with  Shareholder Returns – DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Today the Board of Directors of Amarin Corporation plc (NASDAQ: AMRN) announced details regarding the compensation